April 25, 2024
US FDA accepts sBLA for GSK’s Jemperli for broader endometrial cancer use
GSK has received the US Food and Drug Administration's (FDA) acceptance for its supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) along with standard-of-care chemotherapy (carboplatin and paclitaxel).